Emerg Infect Dis by Gomard, Yann et al.
LETTERS
Julie Haendiges, Marvin Rock, 
Robert A. Myers,  
Eric W. Brown, Peter Evans, 
and Narjol Gonzalez-Escalona
Author	 affiliations:	 Department	 of	 Health	
and	Mental	Hygiene,	Baltimore,	Maryland,	
USA	(J.	Haendiges,	M.	Rock,	R.A.	Myers);	
and	 Food	 and	 Drug	 Administration,	 Col-
lege	Park,	Maryland,	USA	(E.W.	Brown,	P.	 
Evans,	N.	Gonzalez-Escalona)
DOI:	http://dx.doi.org/10.3201/eid2004.130818
References
  1. González-Escalona N, Cachicas V, 
Acevedo C, Rioseco ML, Vergara JA, 
Cabello F, et al. Vibrio parahaemolyticus 
diarrhea, Chile, 1998 and 2004. Emerg 
Infect Dis. 2005;11:129–31. http://dx.doi.
org/10.3201/eid1101.040762
  2. González-Escalona N, Martinez-Urtaza J, 
Romero J, Espejo RT, Jaykus LA, 
DePaola A. Determination of molecular 
phylogenetics of Vibrio parahaemolyticus 
strains by multilocus sequence typing. 
J Bacteriol. 2008;190:2831–40. http://
dx.doi.org/10.1128/JB.01808-07
  3. Nair GB, Ramamurthy T, Bhattacharya 
SK, Dutta B, Takeda Y, Sack DA. Global 
dissemination of Vibrio parahaemolyticus 
serotype O3:K6 and its serovariants. Clin 
Microbiol Rev. 2007;20:39–48. http://
dx.doi.org/10.1128/CMR.00025-06
  4. DePaola A, Kaysner CA, Bowers J, 
Cook DW. Environmental investigations 
of Vibrio parahaemolyticus in oysters 
after outbreaks in Washington, Texas, 
and New York (1997 and 1998). Appl 
Environ Microbiol. 2000;66:4649–54. 
http://dx.doi.org/10.1128/AEM.66.11. 
4649-4654.2000
  5. Abbott SL, Powers C, Kaysner CA, 
Takeda Y, Ishibashi M, Joseph SW, et al. 
Emergence of a restricted bioserovar of 
Vibrio parahaemolyticus as the predomi-
nant cause of vibrio-associated gastro-
enteritis on the West Coast of the United 
States and Mexico. J Clin Microbiol. 
1989;27:2891–3.
  6. Jolley KA, Maiden MC. BIGSdb: scalable 
analysis of bacterial genome variation 
at the population level. BMC Bioin-
formatics. 2010;11:595. http://dx.doi.
org/10.1186/1471-2105-11-595
  7. Jolley KA, Hill DM, Bratcher HB, 
Harrison OB, Feavers IM, Parkhill J, 
et al. Resolution of a meningococ-
cal disease outbreak from whole-
genome sequence data with rapid 
Web-based analysis methods. J Clin Mi-
crobiol. 2012;50:3046–53. http://dx.doi.
org/10.1128/JCM.01312-12
  8. Jolley KA, Maiden MC. Automated 
extraction of typing information for bac-
terial pathogens from whole genome se-
quence data: Neisseria meningitidis as an 
exemplar. Euro Surveill. 2013;18:20379.
  9. Bryant D, Moulton V. Neighbor-net: an 
agglomerative method for the construc-
tion of phylogenetic networks. Mol Biol 
Evol. 2004;21:255–65. http://dx.doi.
org/10.1093/molbev/msh018
10. Makino K, Oshima K, Kurokawa K, 
Yokoyama K, Uda T, Tagomori K, et 
al. Genome sequence of Vibrio para-
haemolyticus: a pathogenic mechanism 
distinct from that of V. cholerae. Lancet. 
2003;361:743–9. http://dx.doi.org/10.1016/
S0140-6736(03)12659-1
Address for correspondence: Narjol Gonzalez-
Escalona, Food and Drug Administration, Center 
for Food and Applied Nutrition, 5100 Paint 
Branch Pkwy, College Park, MD 20740, USA; 
email: narjol.gonzalez-escalona@fda.hhs.gov
Serologic Evidence 
of Leptospirosis in 
Humans, Union of 
the Comoros, 2011
To the Editor: Leptospirosis 
is a worldwide bacterial zoonosis 
caused by infection with pathogenic 
Leptospira spp. (Spirochaetales, Lep-
tospiraceae). Most mammals can be 
infected, but rats are considered the 
main reservoir, maintaining Lepto-
spira spirochetes in the lumen of renal 
tubules and contaminating the envi-
ronment with bacteria-infected urine. 
Transmission to humans is accidental, 
occurring through contact with animal 
secretions or with contaminated envi-
ronmental materials.
In temperate countries, human 
leptospirosis is a sporadic disease; inci-
dence is much higher in the tropics be-
cause climate and environmental con-
ditions are conducive to the survival 
of bacteria, resulting in increased ex-
posure of humans to leptospirosis-
causing pathogens (1). Among islands 
in the southwestern Indian Ocean, hu-
man leptospirosis is endemic to Mayo-
tte, France, and La Réunion (2–4) and 
to the Seychelles, where the incidence 
of leptospirosis is one of the highest 
worldwide (5). Leptospirosis is poorly 
documented in other islands in the re-
gion, including Mauritius, Madagas-
car, and the Union of the Comoros 
(2,6–8). Whether the scant documen-
tation indicates underdiagnosis or re-
flects local epidemiologic specificities 
is unknown. To improve knowledge of 
Leptospira infection in the region, we 
conducted a study in the Union of the 
Comoros to serologically assess the 
presence or absence of leptospirosis 
in humans. The Union of the Comoros 
consists of 3 islands: Grande-Comore, 
Mohéli, and Anjouan. Together with a 
fourth, southern island, Mayotte, these 
islands form the Comoros Archipelago. 
For feasibility reasons, we used 
excess serum samples. Seventy-six 
samples were from healthy volun-
teers who gave informed consent; 318 
clinical blood samples from patients 
had been obtained by private labora-
tories and by the surveillance labora-
tory of the National Malaria Control 
Programme (PNLP) during August 
1–October 8, 2011. The Ministère de 
la Santé, de la Solidarité et de la Pro-
motion du Genre of the Union of the 
Comoros, authorized the serologic 
investigation (authorization no. 1175/
MSSPG/DNS).
We used the microscopic aggluti-
nation test (MAT) to test serum sam-
ples; the MAT was based on a panel 
of 15 Leptospira strains, enabling the 
screening of all recently reported sero-
groups for human and animal cases on 
neighboring Mayotte (2,4,9). A list of 
the tested strains follows, shown as Ge-
nus species Serogroup/Serovar (type 
strain): L. borgpetersenii Ballum/Cas-
tellonis (Castellon 3), L. borgpeterse-
nii Sejroe/Hardjobovis (Sponselee), L. 
borgpetersenii Sejroe/Sejroe (M 84), 
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L. borgpetersenii Tarassovi/Tarassovi 
(Perepelicin), L. interrogans Austra-
lis/Australis (Ballico), L. interrogans 
Autumnalis/Autumnalis (Akiyami A), 
L. interrogans Bataviae/Bataviae (Van 
Tienen), L. interrogans Canicola/Cani-
cola (Hond Utrecht IV), L. interrogans 
Hebdomadis/Hebdomadis (Hebdoma-
dis), L. interrogans Icterohaemor-
rhagiae/Copenhageni (Wijnberg), L. 
interrogans Pyrogenes/Pyrogenes (Sa-
linem), L. kirschneri Cynopteri/Cynop-
teri (3522C), L. kirschneri Grippoty-
phosa/Grippotyphosa (Moskva V), L. 
kirschneri Mini/Undetermined serovar 
(200803703) (9), L. noguchii Panama/
Panama (CZ214K). Each serum sam-
ple was tested at dilutions ranging from 
1:50 to 1:3,200 and considered positive 
when the MAT titer was >100.
Our serologic findings showed 
evidence of Leptospira infection in 
humans on the 3 islands of the Union 
of the Comoros (MAT titers 100–
1,600, geometric mean titer [GMT] 
194). The positivity rate was 10.3% 
(95% CI 4.8–15.9) for samples from 
Mohéli, 4.2% (95% CI 1.4–7.0) for 
samples from Grande-Comore, and 
3.4% (95% CI 0.1–6.7) for samples 
from Anjouan; no significant differ-
ence was found between islands or by 
the age or sex of residents (p>0.05, 
Fisher exact test). Leptospira infec-
tion was more prevalent and MAT 
titers were higher among serum 
samples from the patient group than 
the healthy donor group (20 positive 
samples/318 total vs. 3 positive sam-
ples/76 total; GMT 207 vs. GMT 126), 
but the difference was not significant 
(p>0.05, Fisher exact test). In 78% of 
seropositive serum samples, antibod-
ies reacted with serogroups Australis, 
Bataviae, Grippotyphosa, Panama, Po-
mona, Pyrogenes, Mini, and/or Sejroe. 
MAT titers >100, which are sugges-
tive of more specific antibodies to 
Leptospira, were observed for all se-
rogroups except Australis and Sejroe. 
Pyrogenes serogroup was identified 
in one third of positive samples from 
Mohéli and was associated with the 
highest agglutination titers (Figure).
Our data indicate that Leptospira 
infections do occur in humans in the 
Union of the Comoros; this finding 
is consistent with those in studies re-
porting leptospirosis in persons return-
ing from travel in the Union of the 
Comoros (2,8) and with the detection 
of pathogenic Leptospira spp. in bats 
sampled on these islands (10). The hu-
man leptospirosis–related serologic 
findings in Union of Comoros are most 
comparable to those from neighboring 
Mayotte, where leptospirosis is mainly 
caused by serogroups Mini/Sejroe/
Hebdomadis complex, Pyrogenes, 
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Figure.	 Microagglutination	 test	 results,	 showing	 serologic	 evidence	 of	 leptospirosis	 in	 humans,	 Union	 of	 the	 Comoros,	 2011.	 The	
percentage	of	positive	cases	is	shown	for	each	island;	the	number	below	the	percentage	indicates	the	number	of	positive	serum	samples/
total	number	tested.	The	serogroups	identified	on	each	island	are	shown;	numbers	represent	the	number	of	positive	serum	samples	and,	in	
parentheses,	the	number	of	corresponding	titers.	When	agglutination	was	observed	with	>1	serogroup,	the	serogroup	with	a	titer	difference	
>2	relative	to	other	serogroups	was	considered	to	be	the	infecting	serogroup;	when	no	serogroup	had	a	titer	difference	>2	relative	to	other	
serogroups,	coagglutinins	were	considered	to	be	present	in	the	serum	sample.	Data	for	Mayotte	Island	are	from	previous	studies	(2,4).
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Grippotyphosa, and Pomona and where 
serogroup Icterohaemorraghiae is not 
detectable (2). These findings contrast 
with human leptospirosis findings from 
La Réunion and the Seychelles, where 
the Icterohaemorraghiae serogroup is 
most common (3).
Our MAT-derived data cannot 
discriminate between recent and past 
Leptospira infections, nor can these 
data be used to determine the severity 
of the disease in the Union of the Co-
moros. Nonetheless, the data strongly 
support the presence of human lepto-
spirosis on the 3 islands of the Union 
of the Comoros and emphasize the 
need for a proper diagnosis to ascer-
tain the number of leptospirosis cases 
among the acute febrile illnesses in 
this country.
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Nosocomial  
Drug-Resistant  
Bacteremia in 2  
Cohorts with  
Cryptococcal  
Meningitis, Africa
To the Editor: Cryptococcal 
meningitis is the second leading cause 
of AIDS-related deaths in Africa. The 
prolonged hospitalization necessary 
for optimal management may predis-
pose severely immunocompromised 
persons to hospital-acquired infec-
tions. Limited data are available for 
sub-Saharan Africa regarding mul-
tidrug-resistant infections (1,2). We 
hypothesized that bacteremia was a 
major cause of death.
We reviewed bacteremia episodes 
in cryptococcal meningitis cohorts in 
Kampala, Uganda (n = 115 episodes) 
and Cape Town, South Africa (n = 
72) during November 2010–April 
2013. Data were obtained from the 
prospective cryptococcal optimal an-
tiretroviral therapy timing trial (www.
clinicaltrials.gov:NCT01075152), a 
randomized strategy trial assessing op-
timal antiretroviral therapy timing (n = 
142) and another prospective observa-
tional cohort in Cape Town (n = 45).
We enrolled HIV-infected adults 
who had a first episode of cryptococcal 
meningitis diagnosed by cerebrospinal 
fluid  culture or cryptococcal antigen 
testing. Standardized treatment was in 
accordance with World Health Organi-
zation (WHO) guidelines: amphoteri-
cin deoxycholate, 0.7–1.0 mg/kg/d for 
14 days, and fluconazole, 800 mg/d, 
requiring a minimum 14-day hospi-
talization (3). Each person provided 
written informed consent. Institutional 
review board approval was obtained.
Blood cultures were obtained in 
accordance with physician discre-
tion, typically with new onset fever 
(>38°C) unrelated to amphotericin. 
Two aerobic blood cultures were ob-
tained from 1 peripheral site and not 
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